Thorac Cancer: Retrospective analysis of factors associated with long-term survival in NSCLC patients treated with nivolumab

Nivolumab (nivolumab) is an immune checkpoint inhibitor (ICI) that has transformed the treatment paradigm for advanced non-small cell lung cancer ( NSCLC
) .

However, the factors associated with long-term survival in NSCLC patients treated with ICIs remain unclear

Nivolumab (nivolumab) is an immune checkpoint inhibitor (ICI) that has transformed the treatment paradigm for advanced non-small cell lung cancer ( NSCLC

We retrospectively reviewed the medical records of consecutive nivolumab-treated patients with advanced NSCLC with an ECOG ≤1
.

We defined patients with overall survival (OS) ≥3 years as long-term survivors

We retrospectively reviewed the medical records of consecutive nivolumab-treated patients with advanced NSCLC with an ECOG ≤1

Of the 213 NSCLC patients treated with nivolumab, 162 patients were included in the study, and 51 patients with ECOG > 2 were excluded

The clinical features and indicators that were statistically different between long-term survivors and non-long-term survivors were : age (p = 0.

The overall response rate (ORR) was 19%; complete response (CR) in 4 patients (2%), partial response (PR) in 26 patients (16%), stable disease (SD) in 76 patients (46%), progressive disease (PD) ) 56 cases (35%)

Efficacy assessment

Efficacy assessment

In multivariate analysis, only ΔNLR<1 (OR = 3.
97, 95% CI: 1.
28 12.
3, p = 0.
017) was significantly associated with long-term survival
.

In contrast, younger age (OR = 2.

In multivariate analysis, only ΔNLR<1 (OR = 3.

multi-factor analysis

multi-factor analysis

There was a significant difference in OS between PS=0 and PS=1 patients (HR 0.
41 [95% CI: 0.
24 0.
68], p

OS was significantly different between PS=0 and PS=1 patients (HR 0.
41 [95% CI: 0.
24 0.
68], p OS=0 and PS=1 patients were significantly different (HR 0.
41 [95% CI: 0.
24 0.
68]) .
: 0.
24 0.
68], p

            OS subgroup analysis

            OS subgroup analysis OS subgroup analysis

Taken together, the study demonstrated that ΔNLR <1 was a predictor of long-term survival in nivolumab-treated advanced NSCLC patients compared with ΔNLR ≥1
.

Taken together, the study demonstrated that ΔNLR <1 was a predictor of long-term survival in nivolumab-treated advanced NSCLC patients compared with ΔNLR ≥1
.

Studies have shown that ΔNLR <1 is a predictor of long-term survival in nivolumab-treated advanced NSCLC patients compared with ΔNLR ≥1

Original source:

Murakami Y, Tamiya A, Taniguchi Y, Adachi Y, Enomoto T, Azuma K, Inagaki Y, Kouno S, Matsuda Y, Okishio K, Atagi S.

Murakami Y, Tamiya A, Taniguchi Y, Adachi Y, Enomoto T, Azuma K, Inagaki Y, Kouno S, Matsuda Y, Okishio K, Atagi S.
Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
Thorac Cancer.
2022 Jan 5.
doi: 10.
1111/1759-7714.
14303.
Epub ahead of print.
PMID: 34989133.
Leave a comment here